TY - JOUR
T1 - Antiangiogenic peptides and proteins
T2 - From experimental tools to clinical drugs
AU - Rüegg, Curzio
AU - Hasmim, Meriem
AU - Lejeune, Ferdy J.
AU - Alghisi, Gian Carlo
N1 - Funding Information:
The authors are grateful to Robert Driscoll for critical reading of the manuscript. Work in our laboratory is supported by funds from the Molecular Oncology Program of the National Center for Competence in Research (NCCR), a research instrument of the Swiss National Science Foundation, the Swiss Cancer League/Oncosuisse, the Swiss National Science Foundation, Fondazione San Salvatore, the Leenards Foundation, the Fondation de la Banque Cantonale Vaudoise, the Roche Research Foundation, the Novartis Foundation and the Medic Foundation. We apologize to those colleagues whose work could not be cited due to space limitations.
PY - 2006/4
Y1 - 2006/4
N2 - The formation of a 'tumor-associated vasculature', a process referred to as tumor angiogenesis, is a stromal reaction essential for tumor progression. Inhibition of tumor angiogenesis suppresses tumor growth in many experimental models, thereby indicating that tumor-associated vasculature may be a relevant target to inhibit tumor progression. Among the antiangiogenic molecules reported to date many are peptides and proteins. They include cytokines, chemokines, antibodies to vascular growth factors and growth factor receptors, soluble receptors, fragments derived from extracellular matrix proteins and small synthetic peptides. The polypeptide tumor necrosis factor (TNF, Beromun) was the first drug registered for the regional treatment of human cancer, whose mechanisms of action involved selective disruption of the tumor vasculature. More recently, bevacizumab (Avastin), an antibody against vascular endothelial growth factor (VEGF)-A, was approved as the first systemic antiangiogenic drug that had a significant impact on the survival of patients with advanced colorectal cancer, in combination with chemotherapy. Several additional peptides and antibodies with antiangiogenic activity are currently tested in clinical trials for their therapeutic efficacy. Thus, peptides, polypeptides and antibodies are emerging as leading molecules among the plethora of compounds with antiangiogenic activity. In this article, we will review some of these molecules and discuss their mechanism of action and their potential therapeutic use as anticancer agents in humans.
AB - The formation of a 'tumor-associated vasculature', a process referred to as tumor angiogenesis, is a stromal reaction essential for tumor progression. Inhibition of tumor angiogenesis suppresses tumor growth in many experimental models, thereby indicating that tumor-associated vasculature may be a relevant target to inhibit tumor progression. Among the antiangiogenic molecules reported to date many are peptides and proteins. They include cytokines, chemokines, antibodies to vascular growth factors and growth factor receptors, soluble receptors, fragments derived from extracellular matrix proteins and small synthetic peptides. The polypeptide tumor necrosis factor (TNF, Beromun) was the first drug registered for the regional treatment of human cancer, whose mechanisms of action involved selective disruption of the tumor vasculature. More recently, bevacizumab (Avastin), an antibody against vascular endothelial growth factor (VEGF)-A, was approved as the first systemic antiangiogenic drug that had a significant impact on the survival of patients with advanced colorectal cancer, in combination with chemotherapy. Several additional peptides and antibodies with antiangiogenic activity are currently tested in clinical trials for their therapeutic efficacy. Thus, peptides, polypeptides and antibodies are emerging as leading molecules among the plethora of compounds with antiangiogenic activity. In this article, we will review some of these molecules and discuss their mechanism of action and their potential therapeutic use as anticancer agents in humans.
KW - Antibody
KW - Cancer
KW - Lymphangiogenesis
KW - Peptide
KW - Therapy
KW - Tumor angiogenesis
UR - http://www.scopus.com/inward/record.url?scp=33745120853&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2005.09.003
DO - 10.1016/j.bbcan.2005.09.003
M3 - Review article
C2 - 16263219
AN - SCOPUS:33745120853
SN - 0304-419X
VL - 1765
SP - 155
EP - 177
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 2
ER -